A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.

Molecular Cancer Research : MCR
Elena GerettiM Klagsbrun

Abstract

Neuropilins (NRP1 and NRP2) are coreceptors for vascular endothelial growth factor (VEGF) and mediate angiogenesis and tumor progression. VEGF binds to the NRP1 and NRP2 B domains. Previously, it was shown that mutagenesis of the soluble NRP2 B domain (MutB-NRP2) increased affinity to VEGF by 8-fold. Here, we show that MutB-NRP2 inhibited (125)I-VEGF binding to NRP1, NRP2, and VEGFR-2. It antagonized VEGF-induced VEGFR-2/NRP2 complex formation and inhibited VEGF-induced activation of AKT, a mediator of cell survival, without affecting activation of VEGFR-2. In three-dimensional embryoid bodies, a model of VEGF-induced angiogenesis, MutB-NRP2 inhibited VEGF-induced sprouting. When overexpressed in human melanoma cells, MutB-NRP2 inhibited tumor growth compared with control tumors. Avastin (bevacizumab), a monoclonal antibody to VEGF, inhibited VEGF interactions with VEGFR-2, but not with NRPs. The combination of MutB-NRP2 and Avastin resulted in an enhanced inhibition of human melanoma tumor growth compared with MutB-NRP2 treatment only or Avastin treatment only. In conclusion, these results indicate that MutB-NRP2 is a novel antagonist of VEGF bioactivity and tumor progression.

References

Aug 22, 1997·Cell·A L KolodkinD D Ginty
Dec 2, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·H Q MiaoM Klagsbrun
Oct 26, 2001·Mechanisms of Development·Y HerzogG Neufeld
Mar 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Seiji TakashimaMasatsugu Hori
May 3, 2002·The Journal of Biological Chemistry·Roni MamlukMichael Klagsbrun
Jun 20, 2002·Journal of the National Cancer Institute·Lynn HlatkyJudah Folkman
Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Mar 5, 2003·Advances in Experimental Medicine and Biology·Michael KlagsbrunRoni Mamluk
May 27, 2004·The American Journal of Pathology·Alexander A ParikhLee M Ellis
Oct 27, 2004·Apoptosis : an International Journal on Programmed Cell Death·M OsakiH Ito
Nov 3, 2004·The Journal of Clinical Investigation·Diane R BielenbergMichael Klagsbrun
May 21, 2005·The International Journal of Developmental Biology·Anne EichmannChristiane Breant
Nov 23, 2005·Oncology·Napoleone Ferrara
Dec 24, 2005·The Journal of Biological Chemistry·Mathew A von WronskiAdrian D Nunn
Feb 1, 2006·Experimental Cell Research·Diane R BielenbergMichael Klagsbrun
May 30, 2006·Nature Medicine·Karina YanivBrant M Weinstein
Jul 4, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Terhi KärpänenKari Alitalo
Apr 5, 2007·Proceedings of the National Academy of Sciences of the United States of America·Craig W Vander KooiDaniel J Leahy
May 31, 2007·The Journal of Cell Biology·Lars JakobssonLena Claesson-Welsh
Nov 15, 2007·PloS One·Ling WangDebabrata Mukhopadhyay
Jan 10, 2008·Journal of the National Cancer Institute·Michael J GrayLee M Ellis
Feb 20, 2008·Angiogenesis·Elena GerettiMichael Klagsbrun
Apr 9, 2008·Cancer Cell·Maresa CauntAnil Bagri
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Jul 29, 2008·The Journal of Biological Chemistry·Akio ShimizuMichael Klagsbrun
Sep 6, 2008·Methods in Enzymology·Xiujuan LiMasabumi Shibuya
Dec 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nikolaos A DallasLee M Ellis
Apr 1, 2007·Cell Adhesion & Migration·Elena Geretti, Michael Klagsbrun

❮ Previous
Next ❯

Citations

Oct 22, 2013·Journal of Neuro-oncology·Michael R EpisPeter J Leedman
May 11, 2011·Journal of Gastrointestinal Cancer·Catherine T AnthonyEugene A Woltering
Nov 23, 2013·Nature Reviews. Cancer·Hira Lal Goel, Arthur M Mercurio
Dec 2, 2014·Expert Opinion on Therapeutic Targets·Rosalin MishraGopal C Kundu
Mar 1, 2016·Cell Reports·Hira Lal GoelArthur M Mercurio
Nov 15, 2011·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·Robin J Young, Malcolm W R Reed
Dec 12, 2012·Drug Discovery Today·Snezana Djordjevic, Paul C Driscoll
Oct 19, 2011·Journal of Oncology·Elham Fakhrejahani, Masakazu Toi
Jul 30, 2015·The Cancer Journal·Diane R Bielenberg, Bruce R Zetter
Apr 15, 2015·Endocrine-related Cancer·Simone de BrotNigel P Mongan
May 20, 2014·Biochimica Et Biophysica Acta·Rajesh N Gacche, Rohan J Meshram
Feb 18, 2016·Melanoma Research·Whei F MoriartyRhoda M Alani
Jul 4, 2016·Trends in Pharmacological Sciences·Bruno O Villoutreix, Maria A Miteva
Dec 3, 2016·Cell Adhesion & Migration·Lionel A T MeyerDominique Bagnard
Jan 1, 2011·Cancers·Camille Grandclement, Christophe Borg
Oct 18, 2018·Science Signaling·Ameer L Elaimy, Arthur M Mercurio
Jan 27, 2019·International Journal of Molecular Sciences·Arthur M Mercurio
Jul 5, 2018·International Journal of Cancer. Journal International Du Cancer·Marina KisoFumiaki Sato
Oct 27, 2017·Frontiers in Immunology·Sohini RoyKaustubh Datta
Jun 27, 2019·Proceedings of the National Academy of Sciences of the United States of America·Ameer L ElaimyArthur M Mercurio
Nov 18, 2017·BMC Biology·Sara Sannino, Jeffrey L Brodsky
Apr 17, 2021·Journal of Experimental & Clinical Cancer Research : CR·Elisabetta ValentiniSimona D'Aguanno

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.